Repros Therapeutics Inc. (RPRX) News

Repros Therapeutics Inc. (RPRX): $43.09

-0.06 (-0.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RPRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter RPRX News Items

RPRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RPRX News Highlights

  • For RPRX, its 30 day story count is now at 25.
  • Over the past 16 days, the trend for RPRX's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
  • MD, ALTO and GATE are the most mentioned tickers in articles about RPRX.

Latest RPRX News From Around the Web

Below are the latest news stories about Royalty Pharma plc that investors may wish to consider to help them evaluate RPRX as an investment opportunity.

Royalty Pharma Announces Inaugural Investor Day

NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an inaugural Investor Day in New York City on Tuesday, May 17, 2022, starting at 8:30 a.m. ET. Royalty Pharma senior executives will present on the outlook for royalty funding in life sciences, the company’s capital deployment opportunities and long-term growth targets. The meeting will include live question and answer sessions. Additional details will follow closer to the event. The l

Yahoo | February 16, 2022

Royalty Pharma Reports Q4 and Full Year 2021 Results

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year of 2021 and introduced 2022 Adjusted Cash Receipts ( 1) (a non-GAAP financial measure) guidance.

GlobeNewswire | February 15, 2022

Royalty Pharma reports Q4 results

Royalty Pharma press release (RPRX): Q4 consolidated net income of $54M.Revenue of $576M (+0.7% Y/Y) beats by $32.63M.Full Year 2022 guidance: Adjusted Cash Receipts of $2,225 to…

Seeking Alpha | February 15, 2022

Royalty Pharma plc (RPRX) Q4 2021 Earnings Call Transcript

RPRX earnings call for the period ending December 31, 2021.

The Motley Fool | February 15, 2022

Royalty Pharma Q4 2021 Earnings Preview

Royalty Pharma (NASDAQ:RPRX) is scheduled to announce Q4 earnings results on Tuesday, February 15th, before market open.The consensus EPS Estimate is $0.78 and the consensus…

Seeking Alpha | February 14, 2022

S&co Inc Buys Royalty Pharma PLC, Edwards Lifesciences Corp, Procter & Gamble Co, Sells ...

Boston, MA, based Investment company S&co Inc (Current Portfolio) buys Royalty Pharma PLC, Edwards Lifesciences Corp, Procter & Gamble Co, Palo Alto Networks Inc, Marvell Technology Inc, sells Cloudera Inc, Stericycle Inc, Lions Gate Entertainment Corp, Axalta Coating Systems, Trane Technologies PLC during the 3-months ended 2021Q4, according to the most recent filings of the investment company, S&co Inc.

Yahoo | February 8, 2022

Updated Guidance And Royalty Pharma Financing Demolish Short Thesis For BioCryst Pharmaceuticals

No summary available.

Seeking Alpha | February 7, 2022

Financial Consulate, Inc Buys iShares J.P. ...

Hunt Valley, MD, based Investment company Financial Consulate, Inc (Current Portfolio) buys iShares J.P.

Yahoo | February 7, 2022

Rivian, Robinhood, Bumble: Many top IPOs of 2021 are struggling

Yahoo Finance's Ines Ferre joins the Live show to break down how IPOs of 2021 are faring.

Yahoo | February 7, 2022

Torray LLC Buys General Motors Co, T. Rowe Price Group Inc, Applied Materials Inc, Sells Intel ...

Bethesda, MD, based Investment company Torray LLC (Current Portfolio) buys General Motors Co, T. Rowe Price Group Inc, Applied Materials Inc, Royalty Pharma PLC, Entegris Inc, sells Intel Corp, Loews Corp, Roper Technologies Inc, Bank of America Corp, Lonza Group during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Torray LLC.

Yahoo | February 4, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6396 seconds.